Evidence map›Paper›PMID 42318137›Full record

ArticleMolecular therapy. Advances2026

Deep-sequencing-guided library screening and profiling of AAV capsids in the primate retina.

Youssef Fouani, Dragica Blazevic, Martin Oti, Robert Becker, Benjamin Strobel, Tanja Schönberger, Marius Stephan, Sven Wichert, Felix F Reichel, Immanuel P Seitz and 7 more

Abstract read
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Youssef FouaniEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Dragica BlazevicEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Martin OtiGlobal Computational Innovation, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Robert BeckerEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Benjamin StrobelDrug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Tanja SchönbergerDrug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Marius StephanSystasy Bioscience GmbH, 81699 Munich, Germany.
Sven WichertSystasy Bioscience GmbH, 81699 Munich, Germany.
Felix F ReichelUniversity Eye Hospital, Centre for Ophthalmology, University Hospital Tübingen, 72076 Tübingen, Germany.
Immanuel P SeitzUniversity Eye Hospital, Centre for Ophthalmology, University Hospital Tübingen, 72076 Tübingen, Germany.
Birgit KorbmacherLabcorp Early Development Services GmbH, 48163 Münster, Germany.
Kevin AchbergerNMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany.
Julia RooszNMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany.
Peter LoskillNMI Natural and Medical Sciences Institute at the University of Tübingen, 72770 Reutlingen, Germany.
Udo MaierEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Stefan MichelfelderEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.
Christian SchönEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravitreal (IVT) administration of adeno-associated virus (AAV) vectors is considered a promising strategy for retinal gene therapy. Random peptide-display-based directed evolution has yielded novel AAV capsids with potent retinal bioactivity. However, recent reports on safety risks following IVT AAV administration indicate that significant opportunities remain to further refine AAV vector technology. Here, we performed iterative

Indexed as

AAV vectoradeno-associated viruscapsid engineeringgene therapyretina-tropic AAV vectorssingle-nuclei RNA sequencingsnRNA-seqtranslational NHP model

Identifiers

PMID42318137
PMCPMC13272512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.